Latest Industry Insights
Probing the Proteome With Engineered Nanoparticles
In this interview, Dr. Daniel Hornburg discusses how engineered nanoparticles could help to bridge the gap between proteomics and genomics and transform cancer diagnostics.
Identifying Risk Factors for Long COVID With Single-Cell Proteomics
In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.
When We Become Leaders, How Do We Lead Science Towards Gender Equity?
Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.
A Landscape Assessment of Newborn Screening in Europe
This industry insight explores the findings from a comparative analysis of specific policies governing periodic updates to NBS panels in 30 European countries.
Developing Novel Liquid Biopsy Oncology Tests
In this interview, Aiguo Zhang discusses some of the technologies that DiaCarta has developed within the liquid biopsy space and shares his thoughts on what the future may hold for the field.
Time for Proteomics To Shine
Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.
Exploiting Bacteriophage as a Diagnostic Tool
Technology Networks spoke to Dr. Tomas Richardson from PBD Biotech, to hear more about how bacteriophage can be used to diagnose tuberculosis in both humans and cattle.
CRACKing the Brain’s Cellular Code: An Interview With Professor Jerry Chen
Unpicking our brain's complexity at a cellular level is a mammoth task. How do our genes, cells and electrical impulses come together to decode the world around us? At Boston University Assistant Professor Jerry Chen is trying to crack this code. In this interview, we speak to Chen about his study’s aims, findings and implications.
Measuring Lipids in the Blood Can Predict Disease Risk Decades Before Onset
A new study demonstrated that lipidomic profiling can be used to predict the risk of developing Type 2 diabetes (T2D) and cardiovascular disease (CVD) years before disease onset. We spoke with study lead Professor Chris Lauber to find out more.
Moving Towards the Next Era in Rare Disease Therapeutics
In this two-part interview series, Technology Networks explores some of the reasons behind the difficulties diagnosing and treating rare diseases, and finds out more about recent developments to improve options for patients.